SEC Form 4 · accession 0000905148-16-001679
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy M Shannon
Director
Period of report
Jun 10, 2016
Accepted (ET)
Jun 14, 2016 · 4:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $10.17 | Jun 10, 2016 | A | 14,000 | A | — | Jun 9, 2026 | Common Stock | 14,000 | 14,000 | D |
Explanation of responses
- F1The option vests in full on June 10, 2017 subject to the Reporting Person's continued service to the Issuer through such date.
Remarks
Ex. 24.1 - Power of Attorney (incorporated by reference to the Power of Attorney filed as Exhibit 24.1 to the Form 3 filed by the reporting person on October 7, 2015)